DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Quintiles IMS Holdings, Inc. (NYSE: Q) today announced that its wholly owned subsidiary, Quintiles IMS Incorporated, intends to raise €850 million in gross proceeds through an offering of senior notes due 2025. In connection with the notes offering, the Issuer intends to refinance all of the outstanding term B loans under its senior secured credit facility with an extended, upsized and repriced term B loan facility in an aggregate principal amount equal to $3,065 million equivalent amount comprised of both U.S. dollar denominated term B loans and euro denominated term B loans. The extended term B loans will mature in 2024 and will represent an increase of approximately $600 million from the amount of term B loans currently outstanding. The net proceeds from the notes offering and the refinancing will be used to refinance certain indebtedness of the Issuer, to pay fees and expenses related to the notes offering and the refinancing and for other general corporate purposes, which may include share repurchases, including the repurchase of shares from affiliates and significant shareholders, and future acquisitions. The consummation of the notes offering and the refinancing are each subject to market and other conditions.
About QuintilesIMS
QuintilesIMS (NYSE: Q) is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. Formed through the merger of Quintiles Transnational and IMS Health, QuintilesIMS’s approximately 50,000 employees conduct operations in more than 100 countries. Companies seeking to improve real-world patient outcomes through treatment innovations, care provision and access can leverage QuintilesIMS’s broad range of healthcare information, technology and service solutions to drive new insights and approaches. QuintilesIMS provides solutions that span clinical to commercial, bringing customers a unique opportunity to realize the full potential of innovations and advanced healthcare outcomes.
